Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The objective of this study is to determine the safety, feasibility and efficacy of a bidirectional oxygenation Positive End Expiratory Pressure (PEEP) mouthpiece in coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen by non-rebreather mask.
Description: Pulse oximetry is a way to assess whether or not a patient needs help breathing. Oxygen saturation levels for healthy individuals are 95% and above.
Measure: Change in Oxygen Saturation by Pulse Oximetry Time: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)Description: The number of breaths per minute will be assessed before treatment, during treatment, and 15 minutes after the end of treatment.
Measure: Change in Respiratory Rate Time: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)Description: Heart rate, in beats per minute, will be assessed before treatment, during treatment, and 15 minutes after the end of treatment.
Measure: Change in Heart Rate Time: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)Description: Systolic and diastolic blood pressure will be assessed before treatment, during treatment, and 15 minutes after the end of treatment.
Measure: Change in Blood Pressure Time: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)Description: The participant will be observed for stridor, grunting, nasal flaring, or accessory muscle use. The presence of any of these indicates that increased effort is required for breathing.
Measure: Change in Subjective Work of Breathing Time: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)Description: PaO2 assesses the effects of respiratory distress by measuring the pressure of oxygen dissolved in arterial blood. Normal values are greater than 80 millimeters of mercury (mmHg).
Measure: Change in Partial Pressure of Oxygen (PaO2) Time: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)Description: PaCO2 assesses respiratory state by measuring the pressure of carbon dioxide in blood. and how well carbon dioxide is able to move out of the body. Normal values are between 35 and 45 mmHg. Values below 35 mmHg indicate too little carbon dioxide in blood while values above 45 mmHg mean there is an excess of carbon dioxide.
Measure: Change in Partial Pressure of Carbon Dioxide (PaCO2) Time: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)Description: The pH measures hydrogen ions (H+) in blood. The pH of blood is usually between 7.35 and 7.45. A pH of less than 7.35 means the patient is acidotic while values greater than 7.45 mean the patient is alkalotic.
Measure: Change in pH Time: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)Description: HCO3 is the calculated concentration of bicarbonate in arterial blood. Bicarbonate prevents the pH of blood from becoming too acidic or too basic. Normal values are between 22-26 milliequivalent per liter (mEq/L).
Measure: Change in Bicarbonate (HCO3) Time: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)Description: Oxygen saturation measured by the arterial blood gas test, shows how much oxygen is being carried by hemoglobin in the red blood cells. Normal values are between 95% and 100%
Measure: Change in Oxygen Saturation (O2Sat) by Arterial Blood Gas Test Time: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports